Reviva Pharmaceuticals Holdings - Warrants (25/12/2025) Operating Income

As of the most recent data (June 2026), RVPHW shows a operating income of $-26T. That compares with $-27M in the prior-year period — down 95362271.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RVPHW's operating income is now $-26T (was $-27M) — a 95362271.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Reviva Pharmaceuticals Holdings - Warrants (25/12/2025) is outperforming or lagging.

Tracking RVPHW's operating income over time shows whether Reviva Pharmaceuticals Holdings - Warrants (25/12/2025) is scaling, shrinking, or reshaping that part of the business. The current reading is $-26T That compares with $-27M in the prior-year period — down 95362271.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-26T) with ownership activity and broader fundamentals.

Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s operating income is $-26T; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.